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Immunization with a replication-defective herpes simplex virus 2 mutant
reduces herpes simplex virus 1 infection and prevents ocular disease
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Ocular infections with herpes simplex virus 1 can lead to corneal scarring and blindness, with herpes keratitis being the major infectious cause
of blindness. There is currently no clinically approved vaccine and nearly all developmental vaccines are targeted against HSV-2 and genital
herpes. We tested the ability of an HSV-2 replication-defective virus, a genital herpes vaccine candidate, to protect against HSV-1 corneal
infection. Immunization with HSV-2 dl5-29 reduced viral replication in the cornea, prevented ocular disease and reduced latent infection by the
HSV-1 strain. Therefore, this HSV-2 replication-defective mutant strain may have applications for prevention of herpes keratitis and genital herpes
due to HSV-1 infection.
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Herpes simplex virus (HSV) infects the mucosal epithelium
at both orofacial and genital sites. Historically, HSV-1 has been
the cause of orofacial infections while HSV-2 has been the agent
responsible for genital infections. In a healthy individual,
orofacial infections with HSV-1 are usually mild and free from
serious complications, resulting in localized vesicular lesions
that are resolved within a number of days. However, despite the
apparent innocuous nature of these HSV-1 infections, several
serious complications are also associated with this virus. HSV-1
infection of the brain results in herpes simplex encephalitis
(HSE), while infection of the eye can produce herpetic stromal
keratitis (HSK). Both are associated with severe morbidity.
There are approximately 300,000 cases of ocular HSV-1
infection diagnosed annually in the US (Roizman et al., 2007).
The initial infection involves the corneal epithelium; however,
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doi:10.1016/j.virol.2007.08.030the underlying stroma. This results in HSK and can eventually
lead to blindness (Dawson and Togni, 1976). Generally thought
to be a disease with a strong immunopathologic component
(Doymaz and Rouse, 1992; Verjans et al., 1998), HSK is the
leading cause of infectious corneal blindness in the developed
world (Liesegang, 2001). A preventative therapy would be a
major public health advance. However, the majority of vaccines
currently in development to prevent HSV infection are directed
against HSV-2. This is understandable given the view of HSV-2
as a sexually transmitted disease and the emerging evidence that
genital herpes, i.e., HSV-2, plays an important role in the
acquisition and progression of HIV infection (Corey et al., 2004;
Freeman et al., 2006; Nagot et al., 2007; Wald et al., 2002).
However, given that serious complications such as HSK and
HSE are associated with HSV-1 infection, and the growing
epidemiological evidence suggesting an increase in the
incidence of genital herpes caused by HSV-1 (Malkin, 2004;
Xu et al., 2006), a herpes vaccine should ideally protect against
both HSV-1 and HSV-2. Such a vaccine would be capable of
preventing the serious outcomes associated with HSV-1
infection, such as HSK, and would also be effective against
genital herpes caused by either strain of HSV. With this is mind,
we tested the genital herpes vaccine candidate dl5-29, a
Fig. 2. Immunization with a replication-defective HSV-2 virus reduces facial
swelling following an ocular challenge with HSV-1. Groups of 6 to 8 CD-1 male
mice were immunized with 104, 105 or 106 PFU of HSV-2 dl5-29 virus on days 0
and 21 via subcutaneous inoculation, and a group inoculated with PBS was
included as a negative control. On day 35, all mice were challenged on the eye
with HSV-1 KOS following corneal scarification. Mice were then monitored for
facial swelling for 15 days post-challenge.
228 Rapid Communicationreplication-defective HSV-2 virus, for its ability to protect
against ocular disease caused by HSV-1 infection. This virus has
been shown previously to induce a protective immune response
in both murine and guinea pig models of HSV-2 genital infection
(Da Costa et al., 1999; Hoshino et al., 2005).
Results
To determine the ability of an HSV-2 replication-defective
virus to protect against HSV-1 infection, we immunized mice
with the HSV-2 dl5-29 replication-defective mutant virus and
later challenged the mice with HSV-1 KOS strain virus via the
corneal route, using a corneal infection model described
previously (Leib et al., 1989). Mice were immunized subcuta-
neously on days 0 and 21 with HSV-2 dl5-29 using three
different doses, 104 PFU, 105 PFU or 106 PFU. On day 35,
these mice and mock-immunized control mice were challenged
on the cornea with HSV-1 KOS following scarification. Mice
were then monitored for facial lesions, facial swelling and HSV-
1 shedding in tear film.
Disease
The control mice that had been mock-immunized with PBS
developed both severe facial lesions and pronounced facial
swelling following corneal challenge with HSV-1 (Figs. 1
and 2). When compared to these mice, all mice immunized with
dl5-29 prior to challenge showed a significant reduction in both
lesion severity and facial swelling, regardless of dl5-29 dose.
The highest dose of dl5-29 (106 PFU) completely protected the
mice from developing facial lesions (Fig. 1) and protected five
out of six mice from developing facial swelling (Fig. 2). In the
single mouse in this group where swelling was observed, it was
mild and transient. The intermediate (105 PFU) and low (104Fig. 1. Immunization with a replication-defective HSV-2 virus prevents lesion
development following an ocular challenge with HSV-1. Groups of 6 to 8 CD-1
male mice were immunized with 104, 105 or 106 PFU of HSV-2 dl5-29 virus on
days 0 and 21 via subcutaneous inoculation, and a group inoculated with PBS
was included as a negative control. On day 35, all mice were challenged on the
eye with HSV-1 KOS following corneal scarification. Mice were then monitored
for lesion development for 20 days post-challenge.PFU) doses of dl5-29 provided partial protection against lesion
development and facial swelling (Figs. 1 and 2). When
compared to the control mice, the reductions in lesion severity
seen in the three dl5-29 immunized groups were statistically
significant from day 7 through to day 20 post-challenge, with the
greatest reductions seen on day 15 post-challenge ( pb0.005 for
the 106 PFU group, pb0.01 for the 105 and 104 PFU groups on
day 15). Reductions in facial swelling were statistically sig-
nificant for the 106 and 105 PFU groups between days 5 and 10
post-challenge, and for the 104 PFU group between days 6 and
8 post-challenge. The greatest reductions in facial swelling wereFig. 3. Immunization with a replication-defective HSV-2 virus reduces viral
shedding following ocular challengewithHSV-1.Groups of 6 to 8CD-1malemice
were immunized with varying doses of dl5-29 on days 0 and 21 via subcutaneous
injection, and a group inoculated with PBS was included as a negative control. On
day 35, all mice were challenged on the eye with HSV-1 KOS following corneal
scarification. Eye swabs were collected daily from days 1 to 7 post-challenge, and
viral titers were determined using standard PFU assays. ⁎pb0.01 for PBS vs. 104
dl5-29; pb0.05 for PBS vs. 105 dl5-29; pb0.005 for PBS vs. 106 dl5-29.
⁎⁎pb0.005 for PBS vs. each of the three immunized groups.
229Rapid Communicationseen on days 6 and 7 post-challenge ( pb0.001 for 106 PFU,
pb0.01 for 105 PFU and pb0.05 for 104 PFU on days 6 and 7).
Infection
Following ocular challenge with HSV-1, virus shedding
from the eye was measured in eye swabs taken on days 1 to 7
post-challenge. The control group showed high levels of virus
shedding from days 1 to 6 post-challenge, after which virus
began to clear (Fig. 3). The three groups of mice immunized
with dl5-29 showed a pattern of virus shedding similar to the
controls for the first three days post-challenge. However, from
day 4 post-challenge onward, in correlation with the lesion and
facial swelling observations, all three immunized groups began
to show enhanced clearance of infectious virus as compared to
the control group (Fig. 3). The reduction in virus shedding seen
in these groups was such that by days 5 and 6 post-challenge, all
three groups of mice immunized with dl5-29 showed a
statistically significant reduction in virus shedding as compared
to controls. The level of reduction seen on day 5 post-challenge
was greatest in those mice immunized with 106 PFU dl5-29.
However, by day 6 post-challenge, all three groups showed a
similar level of reduction as compared to controls. By day 7
post-challenge, 50% of the control mice were still shedding
detectable levels of virus, whereas 80% of mice immunized
with 104 PFU dl5-29, 100% of mice immunized with 105 PFU
dl5-29 and 83% of mice immunized with 106 PFU dl5-29 had
cleared infectious virus to below detectable levels (data not
shown).
Reduction in the level of latent virus by immunization with
HSV-2 dl5-29
To determine the ability of dl5-29 virus immunization to
protect against establishment of latent infection by HSV-1, weFig. 4. Levels of latent virus in the trigeminal ganglion are reduced in mice
immunized with a replication-defective HSV-2 virus prior to ocular HSV-1
challenge. Groups of 6 to 8 CD-1 male mice were immunized with varying doses
of dl5-29 on days 0 and 21 via subcutaneous injection, and a group inoculated
with PBS was included as a negative control. On day 35, all mice were
challenged with HSV-1 KOS on the eye following corneal scarification. At 1
month post-challenge, the mice were sacrificed, and the trigeminal ganglia were
removed. Individual TGs were digested and the number of viral genome copies
in each sample was determined using real-time PCR.immunized mice with dl5-29, challenged on the eye with
HSV-1 and then allowed 30 days to pass to enable the
establishment of a latent infection in the trigeminal ganglion
(TG). At this point, the mice were sacrificed, TGs were re-
covered and numbers of HSV-1 viral genome copies were
determined using quantitative PCR. While all mice were found
to harbor latent virus within their TGs, we observed a
statistically significant ( pb0.0005) 10-fold reduction in the
number of viral genomes in the TGs of mice immunized with
106 PFU of dl5-29 as compared to mock-immunized mice
(Fig. 4). As with previous results, mice that had received the
intermediate and low dose of dl5-29 showed a reduction in
latent viral copies as compared to controls, but the reduction
was not as great as seen in those mice that had been im-
munized with the highest dose of dl5-29, indicating a fairly
consistent dose–response.
Discussion
In this study, we observed protection against HSV-1 ocular
disease using a systemically administered vaccine directed
against HSV-2, to our knowledge the first to do so. An earlier
study in a rabbit model of ocular infection used the suboptimal
gB2/gD2 subunit vaccine in MF59 emulsion and a live HSV-1
virus vaccine to demonstrate the requirement for periocular
vaccination when protecting against HSV-1 ocular disease
(Nesburn et al., 1998). The fact that dl5-29 was able to provide
such robust protection against ocular disease following systemic
administration further supports the evidence that this virus
vaccine induces a strong, protective immune response (Da
Costa et al., 1999; Hoshino et al., 2005), and provides evidence
for the first time that this response is effective against HSV-1.
While we did not test the ability of dl5-29 to protect against
HSV-1 genital disease, a recent study observed that systemic
administration of the HSV-2 subunit vaccine gD2/AS04 could
prevent HSV-1 genital disease in a guinea pig model (Bourne et
al., 2003). This finding strengthens the idea that a vaccine
capable of protecting against genital HSV-2 disease, such as
dl5-29 (Da Costa et al., 1999; Hoshino et al., 2005), would
also be capable of preventing HSV-1 genital disease.
We have also shown here that dl5-29 is able to reduce the
latent viral load in the trigeminal ganglion of immunized mice
following HSV-1 challenge. Mice immunized with the highest
does of dl5-29 in this study showed a 10-fold reduction in
latent viral load as compared to controls, equivalent to
reductions in HSV-2 latent viral load seen with dl5-29 in a
guinea pig model of HSV-2 genital infection (Hoshino et al.,
2005), further indicating the potential of this virus vaccine
against both HSV-1 and -2. Reductions in latent virus may be
of particular clinical significance to HSK given the relationship
between latent viral loads and reactivation frequencies. Work
by Sawtell and others has demonstrated that a reduction in the
level of HSV-1 latency correlates with a reduction in the
frequency of reactivation (Sawtell, 1998; Sawtell et al., 2001).
Given that HSK develops over a series of recrudescent
infections, a reduction in reactivation may significantly reduce
the development of HSK in immunized individuals. In addi-
230 Rapid Communicationtion, any reduction in reactivation of either HSV-1 or HSV-2
reduces the opportunities for the virus to spread to susceptible
individuals.
A vaccine capable of protecting against HSV-2 infection is
obviously highly desirable, given the virus' historical position
as the major cause of genital HSV infection and the growing
evidence for a link between genital HSV and an increased risk
of HIV acquisition, transmission and disease progression
(Corey et al., 2004; Freeman et al., 2006; Nagot et al., 2007;
Wald et al., 2002). However, a vaccine capable of protecting
against both types of HSV would be of even greater public
benefit. HSV-1 is the agent responsible for HSK, the leading
cause of infectious corneal blindness, and is the most common
cause of herpes encephalitis. There is also increasing epidemio-
logical evidence that HSV-1 is becoming a significant cause of
genital herpes (Malkin, 2004; Xu et al., 2006), which is likely
to lead to an increase in the incidence of neonatal infections
caused by HSV-1. The replication-defective virus tested in this
study has previously been shown to be effective in preventing
genital disease and reducing levels of latent virus in murine and
guinea pig models of HSV-2 genital infection. It has also been
shown to induce the rapid trafficking of HSV-specific CD8+ T
cells to sites of infection following ocular HSV-2 infection in
mice (Hoshino et al., 2005). The evidence presented in our
current study shows that dl5-29 is able to prevent disease and
reduce levels of latency in a mouse model of HSV-1 ocular
infection. Combined, these data indicate that dl5-29 could
potentially be used as a vaccine to protect against both HSV-1
and HSV-2 infections.
The most obvious caveat to this conclusion is the fact that
previous HSV candidate vaccines, most notably the HSV-2
glycoprotein D subunit vaccines, also showed promise in small
animal studies while failing to show efficacy in later human
trials. However, the subunit vaccines contained only one or two
viral glycoproteins and were designed to elicit CD4+ T cell and
neutralizing antibody responses (Koelle and Corey, 2003). The
replication-defective virus dl5-29 not only provides the immune
system with a much more extensive array of viral epitopes but
also induces a much broader immune response including CD4,
CD8 and antibody responses (Hoshino et al., 2005). Clinical
trials are needed to determine how dl5-29 will perform in
humans.
Materials and methods
Viruses
The HSV-2 replication defective virus, dl5-29, and wild-type
HSV-1 KOS were propagated and assayed for titers on V5-29
(Da Costa et al., 1999) and Vero cells, respectively. The HSV-2
dl5-29 replication-defective mutant virus contains deletions in
the UL5 and UL29 genes (Da Costa et al., 1999, 2000).
Mice
CD-1 outbred male mice were obtained from Charles River
Laboratories and housed under SPF conditions. All animalprotocols were approved by the Institutional Animal Use and
Care Committee.
Immunizations and infections
Mice were immunized with varying doses of dl5-29 in PBS
or with PBS alone via subcutaneous injection in a total volume
of 100 μl. Mice were immunized on days 0 and 21 and then
infected on the cornea on day 35. For the corneal infection (Leib
et al., 1989), mice were anesthetized with 13 μl/g ketamine
(80 mg/ml)/xylazil (12 mg/ml) (Sigma) via intraperitoneal
injection. A 30-gauge needle was used to scratch the eye 20
times, 10 times in a vertical direction and 10 times in a
horizontal direction. A 5 μl aliquot of HSV-1 KOS containing
2×106 PFU was placed on the eye and allowed to adsorb before
the mice regained consciousness.
Viral shedding
On days 1 to 7 post-challenge, mice were anesthetized briefly
with Isoflurane (Abbott Labs); sterile cotton applicators (Puritan
Medical Products) soaked in Dulbecco's minimum essential
medium (DMEM) (Invitrogen) were used to collect the fluid on
each eye. For each mouse, the samples from both eyes were
placed together in a 3 ml glass vial containing 1 ml sterile
DMEM and stored at −80 °C until needed. To determine viral
shedding, plaque-forming assays were performedwhereby serial
dilutions of the medium in each vial were plated onto confluent
Vero cell monolayers (Morrison and Knipe, 1994). Statistical
analysis was performed using the unpaired Student's t-test.
Facial lesions and swelling
Between days 5 and 15 post-challenge, mice were monitored
for facial swelling. Facial swelling scores were based on the
presence of swelling in 3 different regions of the left and right
sides of the face. Swelling in each individual area earned a score
of 1, with a maximum score of 6 possible. Mice were monitored
for facial lesions between day 6, when lesions first appeared,
and day 20 post-challenge. Lesions were scored based on the
severity of lesions on the left and right sides of the face. Each
side was scored from 0 to 4, with 0 indicating no lesions and 4
indicating severe lesions. The scores from either side were then
added together, giving a maximum possible score of 8.
Quantitative PCR
On day 30 post-ocular challenge, the TGs were removed
from each mouse and immediately placed on dry ice before
being transferred to −80 °C until required. Each TG was
digested overnight at 56 °C in proteinase K digestion buffer
(200 μg/ml proteinase K, 25 mM KCl, 5 mM Tris, pH 9,
500 μM MgCl2). The exact volume of each sample was then
determined, and 1 μl of each sample was used in a real-time
PCR reaction. Real-time PCR amplification and detection were
performed using an ABI 770 Sequence Detector, with HSV-1
thymidine kinase gene specific primers used to detect HSV-1
231Rapid CommunicationKOS viral DNA: Forward primer: ACCCGCTTAACAGCGT-
CAACA, Reverse primer: CCAAAGAGGTGCGGGAGTTT
(Katz et al., 1990; McKnight, 1980). Reactions were performed
in 10 μl volumes containing SYBRGreen PCR mix and primers
at a final concentration of 500 nM. PCR reactions were am-
plified at 50 °C for 2 min, 95 °C for 10 min, then 40 cycles of
95 °C for 15 s and 60 °C for 1 min.
In each reaction, a standard curve was included. Total
genomic DNA was extracted from HSV-1 infected Vero cells
using the QIAGEN DNeasy tissue kit. Viral DNAwas obtained
by running the total genomic DNA on a 0.9% LowMelt agarose
gel and extracting the viral band. The viral DNA was then
quantified, using absorbance and comparison to mass standards
on a gel, to determine the number of viral genomes/μl. To create
a standard curve, the purified HSV-1 KOS DNA was serially
diluted such that each reaction contained 10-fold dilutions of
HSV-1 DNA from 2×107 to 2×100 molecules.
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